INCY - Incyte Corporation

-

$undefined

N/A

(N/A)

Incyte Corporation NasdaqGS:INCY Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Location: 1801 Augustine Cut-Off, Wilmington, DE, 19803, United States | Website: https://www.incyte.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

10.42B

Cash

2.409B

Avg Qtr Burn

N/A

Short % of Float

5.88%

Insider Ownership

2.22%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ZYNYZ (Retifanlimab) (anti-PD-1 mAb) Details
Solid tumor/s, Cancer, Metastatic merkel cell carcinoma, Skin cancer

Approved

Quarterly sales

Pemazyre® (pemigatinib) Details
8p11 myeloproliferative syndrome

Approved

Quarterly sales

Niktimvo™ (axatilimab-csfr) Details
Graft-versus-host disease

Approved

Quarterly sales

ZYNYZ (Retifanlimab) (anti-PD-1 mAb) Details
Solid tumor/s, Cancer, Squamous cell carcinoma of the anal canal

BLA

Submission

Tafasitamab (Monjuvi®) + Lenalidomide & Rituximab Details
Follicular lymphoma, Relapsed/ refractory lymphoma

BLA

Submission

ZYNYZ (Retifanlimab) (anti-PD-1 mAb) Details
Solid tumor/s, Cancer, Non-small cell lung carcinoma

BLA

Submission

NDA

FDA meeting

Phase 3

Data readout

Phase 3

Data readout

Povorcitinib (JAK1) Details
Hidradenitis suppurativa

Phase 3

Update

Phase 3

Update

Phase 3

Initiation

Phase 3

Initiation

Phase 3

Initiation

Phase 2

Data readout

Povorcitinib Details
Chronic spontaneous urticaria

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Data readout

Phase 1

Data readout

Phase 1

Data readout

Failed

Discontinued

Failed

Discontinued